Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
about
New Developments in Chronic Myeloid Leukemia: Implications for TherapyBiomarkers for determining the prognosis in chronic myelogenous leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsCancer stem cells in basic science and in translational oncology: can we translate into clinical application?Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.Chronic myelogenous leukemia: treatment and monitoring.Monitoring response and resistance to treatment in chronic myeloid leukemia.Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitorsThe bone marrow microenvironment as a sanctuary for minimal residual disease in CML.Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.Recommendations of the canadian consensus group on the management of chronic myeloid leukemia.Complex translocation involving four chromosomes in a novel Philadelphia-positive chronic myeloid leukemia case.Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar.Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase.A new t(9;11;20;22)(q34;p11.2;q11.21;q11) in a Philadelphia-positive chronic myeloid leukemia case.Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapyManagement of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.Novel complex translocation involving 5 different chromosomes in a chronic myeloid leukemia with Philadelphia chromosome: a case report.Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.Selection of therapy: rational decisions based on molecular events.Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?A rare case of chronic myeloid leukemia with secondary chromosomal changes including partial trisomy 17q21 to 17qter and partial monosomy of 16p13.3.Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia.Improved prediction of clinical outcome in chronic myeloid leukemia.Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
P2860
Q26745669-B5E4113C-C372-4DCD-9930-825717B523C5Q26824660-54B3CB82-56C2-4B20-964D-0E73BCCE0FA1Q27028181-1F98A7F5-AB4E-4F88-8F7F-92FC29B105ECQ28081844-D567EF4D-5FFC-45D9-97E9-67959A380009Q33357697-A9906EA0-6F57-4EB3-BF5F-7022B16E6CC8Q33518973-EEE6C0DC-F661-4AE6-A877-EFFA8B2E1C43Q33766467-58B5BB3D-D1B5-43FF-8A23-AAA7A1C28966Q34617628-EBE365FE-92F8-43DA-96C2-2FCFA5DA7737Q34761663-6F1508F1-0032-4379-8650-F7C0855B0395Q35404394-E316D819-9E27-4FEB-A44B-A8D58ACE9BC8Q35595870-D372C653-8AAB-4C22-89A4-19485E353F27Q35773205-C4AACCEE-EBA7-4D4F-9615-6EF2F5BCEECDQ35816396-D1C4D1A5-9FA6-4493-9879-DEA0172714A5Q35819214-47146667-6995-43D7-B46C-E72251B4423CQ35847727-E724D1E6-181D-4EF8-AD13-DB44E55A1261Q36089086-468BA880-FC34-4160-B56E-AEC774A68693Q36135775-543F151E-04BF-4C3E-8C41-0A161CE8C41AQ36219652-7D919385-5E8E-4529-8F18-1063BB8C2D26Q36331689-7F8DE4AE-3AFB-491E-AEC2-156D9BCD3B6FQ36364850-E7FF738E-B3A0-4BA7-8A38-732563E6093EQ36387433-DDE32239-1DC6-42FD-A2E2-7FEF11079C6DQ36611832-EF3C2EC3-8EC8-44EE-83AF-2076C2C2C10EQ37025991-55C58695-95DB-4C2D-9D72-CD884F56458DQ37026032-0CB515FF-A724-4585-B9F7-6836F196D68FQ37295261-0D9C46D0-C2AA-45FC-BE94-8E3D23D5BBB4Q37360559-6A678DD5-71E7-46B4-8722-BF225B6929D5Q37420613-9B1FDD8A-0251-42CF-BF00-083D0E64E5DCQ37428659-DDF13C8C-9268-4F1A-8E8B-90E543E5625CQ37582459-391C5BEC-F235-494F-BBF3-9638A68D434EQ37647076-B649274B-35E3-4A9F-9FA3-B36B75B9D349Q37810110-5CF71251-C18A-40B4-90B3-E24CA0A960D1Q37952910-3AB35A45-E797-4171-824F-D5BB778183C2Q38095956-243DEE5D-B525-47B8-8631-8A9BFF8A18DCQ38148233-2ED756DF-6D3E-480E-BECF-E7A1553D8119Q39516382-2F8629F8-3600-43D0-AE0F-02A3004B3804Q39877710-9D9C7E7F-710D-46CE-AEFB-2846EAC2F00EQ40607863-104CEBC1-E94E-4009-A519-911835B9F008Q41609451-5F2411F1-CA1C-4DE3-8D59-E52FD97E1217Q41650682-226EABC1-3FBE-4218-ADDF-B270A22ED9C2Q41948234-F073E150-6F00-4258-940F-8A1461E579CA
P2860
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Prognostic significance of cyt ...... on imatinib mesylate therapy.
@en
Prognostic significance of cyt ...... on imatinib mesylate therapy.
@nl
type
label
Prognostic significance of cyt ...... on imatinib mesylate therapy.
@en
Prognostic significance of cyt ...... on imatinib mesylate therapy.
@nl
prefLabel
Prognostic significance of cyt ...... on imatinib mesylate therapy.
@en
Prognostic significance of cyt ...... on imatinib mesylate therapy.
@nl
P2093
P50
P1433
P1476
Prognostic significance of cyt ...... on imatinib mesylate therapy.
@en
P2093
Allessandra Ferrajoli
Deborah A Thomas
Jianqin Shan
Moshe Talpaz
P304
P356
10.1182/BLOOD-2002-09-2790
P407
P50
P577
2003-01-30T00:00:00Z